LAWRENCE, Mass., Nov. 16, 2016 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading medical technology
company focused on advancing renal care, today announced new
findings demonstrating positive outcomes related to more frequent
hemodialysis with the NxStage® System One™. The data will be
presented at the American Society of Nephrology (ASN) Kidney Week
2016 Annual Meeting being held November
15-20, 2016, in Chicago.
The research was conducted by Dr. Eric D.
Weinhandl, PhD, MS, NxStage Clinical Epidemiologist and
Adjunct Assistant Professor of Pharmaceutical Care & Health
Systems at the University of Minnesota,
Dr. Allan J. Collins, NxStage Senior
Medical Advisor and Professor of Medicine at the University of Minnesota, and Dr Fredric O. Finkelstein, Clinical Professor of
Medicine at Yale University. Conference attendees can meet
with NxStage representatives in booth 1135.
Researchers will present data from a number of studies that
highlight the benefits of more frequent hemodialysis (typically
performed at home) versus conventional in-center hemodialysis,
including:
- Better Outcomes and Higher Quality of Life: According to
a meta-analysis of randomized clinical trials, significant
beneficial effects on left ventricular hypertrophy, blood pressure,
phosphorus balance and health-related quality of life;
- Lower Cost of Care: A $10,000 per patient-year decrease in Medicare
payments for inpatient care, post-acute care, and physician and
supplier services; and,
- Improved Clinical Outcomes in Incident Dialysis
Patients: Higher transplant rates and lower death rates for
incident dialysis patients on more frequent home hemodialysis.
"Both randomized clinical trials and observational research
indicate that frequent home hemodialysis is an efficacious therapy
option for dialysis patients, including new patients, patients with
key cardiovascular risk factors, and those with poor quality of
life," said Dr. Weinhandl. "Importantly, this research also shows
that these patients can benefit from this therapy option without
burdening the system with increased cost."
"Data continues to reaffirm that more frequent hemodialysis with
the System One provides better patient health outcomes at a lower
cost of care," said Joe Turk,
President of NxStage Medical. "Based upon compelling evidence, more
frequent home hemodialysis should be considered the standard of
care for a growing number dialysis patients. We are excited to be
sharing this data with the entire renal care community and look
forward to working together to provide greater patient access to
this life-changing therapy option."
Currently, over 95% percent of hemodialysis patients in the U.S.
receive treatment three times per week, despite overwhelming
evidence of clinical and lifestyle benefits for patients on more
frequent hemodialysis. The NxStage System One is a simple, flexible
and portable hemodialysis system that provides a wide range of
dialysis therapy options, including home, more frequent and
nocturnal dialysis. Visit www.nxstage.com for more information on
therapy options with the System One.
Dr. Eric Weinhandl will conduct
an oral presentation on Thursday, November
17, 2016 at 5:18 p.m. CT.
Posters numbers 1114, 1115, 1116, and 1117, will be displayed
Saturday, November 19, 2016 from
9:30 a.m. – 2:30 p.m. CT on the scientific exposition
floor.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. In addition, NxStage's Nx2me
Connected Health platform collects important NxStage System One and
patient information for flexible viewing, monitoring and
reporting that may improve patient management and patient
retention, as well as simplify alternative site care.
http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc.
(Nasdaq: NXTM) is a leading medical technology company,
headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
also has established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's websites
at www.nxstage.com and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2016.
NxStage is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-data-shows-better-outcomes-higher-quality-of-life-lower-cost-of-care-and-increased-likelihood-for-transplant-with-more-frequent-hemodialysis-using-the-nxstage-system-one-300363937.html
SOURCE NxStage Medical, Inc.